Unitary patent granted

Pharmista has now been granted a Unitary Patent for their IP by the European Patent Office. This protects their intellectual property in 17 EU member states and the United Kingdom.

Pharmista CEO, Alice Mattsson said. “The Unitary Patent provides us with a high level of protection for our invention. The reusable device is being developed in the first instance, to provide a high-quality alternative in the pregnancy test market. Moving forward, we can use this technology to help diagnose other conditions relating to health and wellbeing”.

 RAPIvD CEO, Dr Robert Porter commented. “Pharmista continue to make strong progress with their product development and this is another milestone that they have passed successfully. The protection afforded by the Unitary Patent from the EPO gives them the confidence to focus on getting the pregnancy device to market as well as planning future product applications”.